[go: up one dir, main page]

WO2022194022A1 - Procédé de préparation de sébacate de nalbuphine et de son intermédiaire - Google Patents

Procédé de préparation de sébacate de nalbuphine et de son intermédiaire Download PDF

Info

Publication number
WO2022194022A1
WO2022194022A1 PCT/CN2022/080164 CN2022080164W WO2022194022A1 WO 2022194022 A1 WO2022194022 A1 WO 2022194022A1 CN 2022080164 W CN2022080164 W CN 2022080164W WO 2022194022 A1 WO2022194022 A1 WO 2022194022A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound represented
acid
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/080164
Other languages
English (en)
Chinese (zh)
Inventor
张玲
蒋钰
陈帅
蔡兆雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Nhwa Pharmaceutical Research Co Ltd
Nhwa Pharmaceutical Corp
Original Assignee
Suzhou Nhwa Pharmaceutical Research Co Ltd
Nhwa Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Nhwa Pharmaceutical Research Co Ltd, Nhwa Pharmaceutical Corp filed Critical Suzhou Nhwa Pharmaceutical Research Co Ltd
Priority to CN202280021384.8A priority Critical patent/CN117083277A/zh
Publication of WO2022194022A1 publication Critical patent/WO2022194022A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems

Definitions

  • the synthetic route of nalbuphine sebacate mainly includes the following ways:
  • the present invention provides a formula (1) The preparation method of the shown dinalbuphine diacid ester or its pharmaceutically acceptable salt and its intermediate.
  • the compound shown is the starting material, which is prepared by esterification with an esterification reagent to obtain formula (2)
  • the 6-keto group is reduced to 6-hydroxyl group to prepare the dinalbuphine diate represented by the formula (1) or a pharmaceutically acceptable salt thereof.
  • the compound represented by the formula (2) undergoes a reduction reaction in the organic solvent (A) under the action of an acid and a reducing agent to prepare the compound represented by the formula (1).
  • the present invention provides a dinalbuphine sebacate or a pharmaceutically acceptable salt thereof, and a method for preparing an intermediate thereof, comprising using a compound represented by the starting material formula (IV) , through reductive amination reaction, the compound shown in formula (III) is prepared, and then the compound shown in formula (II) is prepared through esterification reaction with sebacyl chloride, and then the 6-keto group is reduced to 6-hydroxyl group to prepare Dinalbuphine sebacate or a pharmaceutically acceptable salt thereof.
  • the present invention provides a preparation method of a compound represented by formula (II) or a pharmaceutically acceptable salt thereof, comprising:
  • the present invention further provides a method for preparing a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, that is, a method for preparing dinalbuphine sebacate or a pharmaceutically acceptable salt thereof, comprising:
  • acyloxyborohydride refers to a compound having the structure
  • each R 1 is a C 1-3 alkyl group and is the same, such as methyl, ethyl and propyl
  • M + is a Salt-forming cation, in the present invention, M + can be sodium ion, potassium ion, lithium ion and ammonium ion;
  • hydrochloric acid in the present invention refers to a compound capable of donating H + , and the present invention is preferably a corresponding organic acid or inorganic acid, such as formic acid, acetic acid, hydrochloric acid and the like.
  • the molar ratio of the triethylamine to the compound represented by formula (III) is selected from 1:1 ⁇ 10:1, preferably 1:1 ⁇ 5:1, more preferably 1:1 ⁇ 3:1, such as 1:1 ⁇ 2:1
  • the post-treatment process includes, after the reaction, adding an aqueous ammonium chloride solution, then filtering, and adding an organic solvent for crystallization, and the crystallization includes adding an inert solvent for crystallization, cooling and crystallization One or more methods of crystallization or stirring crystallization.
  • the C 1-3 carboxylic acid is selected from formic acid, acetic acid, oxalic acid and propionic acid, preferably formic acid and acetic acid, such as formic acid.
  • the base is selected from the group consisting of sodium carbonate, potassium carbonate, triethylamine, diisopropylethylamine, tetramethylethylenediamine and trimethylamine, preferably triethylamine.
  • the hydrogen donor agent is selected from formic acid, acetic acid and hydrochloric acid, preferably formic acid.
  • the molar ratio of the triethylamine to the compound represented by formula (IV) is selected from 1:1-10:1, preferably 1.5:1-6:1, for example, preferably 2:1-5 :1, 3:1 to 5:1 or 3:1 to 4:1.
  • the molar ratio of the compound represented by the formula (IV) and the transition metal catalyst is selected from 1:0.001 ⁇ 1:0.03, for example 1:0.001 ⁇ 1:0.01, preferably 1:0.001 ⁇ 1: 0.005, more preferably 1:0.002 to 1:0.005.
  • the compound represented by the formula (2) undergoes a reduction reaction in the organic solvent (A) under the action of an acid and a reducing agent to prepare the compound represented by the formula (1).
  • the reducing agent is an acyloxy borohydride compound
  • the organic solvent (A) is selected from nitrile solvents, saturated carboxylate solvents of C 2-5 , benzene solvents, ether solvents, C 1-3 saturated monohydric alcohol solvent and C 1-3 halogenated alkane solvent, preferably nitrile solvent.
  • the C 2-5 saturated carboxylic acid ester solvent is selected from methyl formate, methyl acetate, ethyl formate, ethyl acetate, propyl formate, methyl propionate, propionic acid Ethyl and propyl acetate, preferably ethyl acetate.
  • the benzene-based solvent is selected from toluene, ethylbenzene, 1,2-xylene and 1,3-xylene, preferably toluene.
  • the C 1-3 saturated monohydric alcohol is selected from methanol, ethanol and isopropanol, preferably methanol and ethanol, such as methanol.
  • the organic solvent (A) is selected from acetonitrile, ethyl acetate, tetrahydrofuran, toluene and dichloromethane, preferably acetonitrile.
  • the acyloxyammonium borohydride compounds are selected from triacetoxyammonium borohydride compounds, tripropionyloxyammonium borohydride compounds, and tributyryloxyammonium borohydride compounds Compounds and trivaleryloxyammonium borohydride compounds, preferably triacetoxyammonium borohydride compounds.
  • the triacetoxyammonium borohydride compound is selected from the group consisting of tetramethylammonium triacetoxyborohydride, tetraethylammonium triacetoxyborohydride, and tetrapropylammonium triacetoxyborohydride and tetrabutylammonium triacetoxyborohydride, preferably tetramethylammonium triacetoxyborohydride.
  • the tributyryloxy ammonium borohydride compound is selected from the group consisting of tributyryloxy tetramethylammonium borohydride, tributyryloxy tetraethyl ammonium borohydride, tributyryloxy borohydride Tetrapropylammonium hydride and tetrabutylammonium tributyryloxyborohydride, preferably tetramethylammonium tributyryloxyborohydride.
  • the volume ratio of the organic solvent (A) to the acid is selected from 0.5:1-9:1, such as 1:1-9:1, preferably 1:1-5:1, more Preferably 1:1 to 3:1, for example 1:1.
  • the molar ratio of the reducing agent to the compound represented by formula (2) is selected from 1:1-5:1, preferably 2:1-5:1, for example 2:1-3:1 , or 3.1:1, 3.2:1, 3.3:1, 3.4:1, 3.5:1, 3.6:1, 3.7:1, 3.8:1, 3.9:1, 4:1, etc.
  • a post-processing process is also included, for example, extraction is performed by an organic solvent commonly used in the art, and washing is performed by an aqueous solution of a saturated salt commonly used in the art ; After the extraction process and the washing process are carried out sequentially or staggered, the process of drying and/or concentrating the organic phase may be further included.
  • the saturated salt solution in the post-treatment process, can be selected with reference to common solutions in the art, preferably saturated aqueous sodium bicarbonate solution and saturated aqueous sodium chloride solution.
  • FIG. 4 shows the HPLC spectrum of the compound of formula I prepared by the method of Example 3.1.3;
  • 14-Hydroxydihydronormorphone (20 g, 1 eq) and anhydrous methanol (400 mL) were sequentially added to a 1 L single-neck flask, and nitrogen was replaced three times, 3 eq of cyclobutylcarboxaldehyde was added, and the reaction was stirred at 70° C. for 1 hour.
  • the reaction solution was cooled to room temperature, and in another 250mL single-necked bottle, 10eq of formic acid was slowly added to 100mL of anhydrous methanol of 4eq of triethylamine, stirred for 5 minutes, and added to the aforementioned first single-necked bottle, and a catalytic amount (113mg) was added.
  • the specific preparation method is prepared by referring to the method described in Example 15 of patent TW399056B, the yield of di-nalbuphine sebacate is 57%, the HPLC shows that the purity is 80.1%, and there are more nalbuphine sebacate monoesters in the reaction produced and difficult to remove.
  • Test result In the new preparation process of nalbuphine sebacate according to the present invention, the compound represented by formula (III) is used as the starting material to be esterified to prepare the compound represented by formula (II), and then the compound represented by formula (II) is prepared by esterification.
  • the compound shown in II is reduced to prepare dinalbuphine sebacate, which not only significantly improves the yield and purity of the final product (92% vs 43-57%; 98.8% vs 73.4% ⁇ 80.1%), and the reaction conditions are mild and controllable, the reagents used are less toxic (triethylamine and dichloromethane are less toxic than dimethylamine pyridine and bis(2-pyridine) carbonate), and the reaction time is significantly shortened (1 hours vs 18 hours), which is not only green and environmentally friendly, but also conducive to large-scale pharmaceutical industrial production, significantly reducing production costs and production risks.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé de préparation de sébacate de nalbuphine et d'un intermédiaire de celui-ci. Le procédé permet de préparer du sébacate de nalbuphine de manière efficace, commode et sans danger, et la pureté et le rendement du produit final de sébacate de nalbuphine peuvent être améliorés de manière considérable.
PCT/CN2022/080164 2021-03-15 2022-03-10 Procédé de préparation de sébacate de nalbuphine et de son intermédiaire Ceased WO2022194022A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280021384.8A CN117083277A (zh) 2021-03-15 2022-03-10 一种纳布啡癸二酸酯及其中间体的制备方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110276968 2021-03-15
CN202110276968.7 2021-03-15

Publications (1)

Publication Number Publication Date
WO2022194022A1 true WO2022194022A1 (fr) 2022-09-22

Family

ID=83321533

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/080164 Ceased WO2022194022A1 (fr) 2021-03-15 2022-03-10 Procédé de préparation de sébacate de nalbuphine et de son intermédiaire

Country Status (2)

Country Link
CN (1) CN117083277A (fr)
WO (1) WO2022194022A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1321643A (zh) * 2000-04-28 2001-11-14 胡幼圃 那布扶林多元酯衍生物及其制造方法
CN1500786A (zh) * 2002-11-12 2004-06-02 ���ŷ�������ҽԺ 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物
WO2014190270A1 (fr) * 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limited Analogues de morphane et morphinane, et procédés d'utilisation
WO2015066443A1 (fr) * 2013-11-01 2015-05-07 Mallinckrodt Llc Préparation pratique de morphinan-6-ols n-substitués à partir de morphinan-6-ones
CN111116597A (zh) * 2018-10-31 2020-05-08 扬子江药业集团江苏紫龙药业有限公司 一种纳布啡游离碱的制备方法
WO2021024039A1 (fr) * 2019-08-07 2021-02-11 Ripple Therapeutics Corporation Compositions et méthodes de traitement de la douleur et de troubles de la dépendance

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4024992B2 (ja) * 2000-04-27 2007-12-19 オリバー ヤオ−プ フ ポリナルブフィン誘導体及びそれを製造するための方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1321643A (zh) * 2000-04-28 2001-11-14 胡幼圃 那布扶林多元酯衍生物及其制造方法
CN1500786A (zh) * 2002-11-12 2004-06-02 ���ŷ�������ҽԺ 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物
WO2014190270A1 (fr) * 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limited Analogues de morphane et morphinane, et procédés d'utilisation
WO2015066443A1 (fr) * 2013-11-01 2015-05-07 Mallinckrodt Llc Préparation pratique de morphinan-6-ols n-substitués à partir de morphinan-6-ones
CN111116597A (zh) * 2018-10-31 2020-05-08 扬子江药业集团江苏紫龙药业有限公司 一种纳布啡游离碱的制备方法
WO2021024039A1 (fr) * 2019-08-07 2021-02-11 Ripple Therapeutics Corporation Compositions et méthodes de traitement de la douleur et de troubles de la dépendance

Also Published As

Publication number Publication date
CN117083277A (zh) 2023-11-17

Similar Documents

Publication Publication Date Title
TWI710547B (zh) 抗病毒化合物之合成
WO2022242278A1 (fr) Procédés de préparation de l'upadacitinib et d'un intermédiaire de celui-ci
CN101679257B (zh) 合成8-[{1-(3,5-双-(三氟甲基)苯基)-乙氧基}-甲基]-8-苯基-1,7-二氮杂-螺[4.5]癸-2-酮化合物的方法和中间体
TR201816203T4 (tr) Sübstitüe edilmiş (z)-alfa-floro-beta-amıno-akrilaldehitlerin üretilmesine yönelik yöntem.
AU2002255803A1 (en) Process to prepare oxazolidinones
EP1380121A2 (fr) Procede de preparation d'oxazolidinones
JP6118412B2 (ja) 抗ウイルス化合物の合成
JP2025072490A (ja) Ｘｐｏ１阻害剤の調製プロセス及びｘｐｏ１阻害剤の調製に用いられる中間体
JP7365349B2 (ja) 一酸化窒素を供与するプロスタグランジン類似体の製造方法
CN103183673B (zh) (s,s)-2,8-二氮杂双环[4,3,0]壬烷的合成方法
CN105732754B (zh) 烷基酸睾酮化合物的合成方法
EP3386947A1 (fr) Procédé de production d'ester alkylique de l'acide n-rétinoylcystéique
CN109796457A (zh) 一种2-(3-(氮杂环丁烷-3-基)哌啶-1-基)乙基-1-醇的制备方法及其应用
WO2022194022A1 (fr) Procédé de préparation de sébacate de nalbuphine et de son intermédiaire
CN110183445A (zh) 莫西沙星及其衍生物的合成方法
CN111518110A (zh) 一种海鞘素化合物及其中间体的制备方法
CN110317170B (zh) 一种3-菲啶基甲酸丙酯类化合物的绿色合成方法
KR20150091150A (ko) 트라보프로스트의 제조 방법
CN110343117B (zh) 青蒿素衍生物的制备方法
CN104072495A (zh) 天然产物生物碱Aaptamine的制备方法
JPH04364188A (ja) ３−アルコキシメチル−セファロスポリン誘導体の製法
CN109485661B (zh) [3+2]环加成合成苯并唑并噁唑类化合物的方法
CN119100966B (zh) 一种溴代吡咯甲酸甲酯的合成方法
JP2022532875A (ja) Ｃｒａｃチャネル阻害剤の合成
CN111808040B (zh) 多构型2-氧代噁唑烷-4-羧酸类化合物的合成方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22770377

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280021384.8

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22770377

Country of ref document: EP

Kind code of ref document: A1